2316-10-1

Usage

Uses

Used in Pharmaceutical Industry:
(3aS,4R,9aS)-4-(3,4-dihydroxyphenyl)-6,7-dihydroxy-3a,4,9,9a-tetrahydronaphtho[2,3-c]furan-1(3H)-one is used as a potential therapeutic agent for the development of drugs targeting cancer and neurodegenerative diseases due to its antioxidant and anti-inflammatory properties. Further research is required to fully understand its biological activity and therapeutic benefits.

Upstream product

• 518-55-8 conidendrin 

Downstream Products

• 6323-25-7 (3aR)-6,7-bis-benzoyloxy-4c-(3,4-bis-benzoyloxy-phenyl)-(3ar,9at)-3a,4,9,9a-tetrahydro-3H-naphtho[2,3-c]furan-1-one 
• 2643-01-8 β-nor-conidendrin 

Relevant academic research and scientific papers

A selective de-O-methylation of guaiacyl lignans to corresponding catechol derivatives by 2-iodoxybenzoic acid (IBX). the role of the catechol moiety on the toxicity of lignans

We report here the first selective de-O-methylation of a large panel of guaiacyl lignans to the corresponding catechol derivatives by using IBX as primary oxidant under green conditions (dimethyl carbonate-H2O solvent) through an in situ reduction procedure. The influence of the catechol moiety on the cytotoxicity and genotoxicity of new lignan derivatives has been investigated. The results obtained indicated that the presence of the catechol moiety sharply enhances the clastogenic potential (e.g. induction of chromosomal aberrations), the cytotoxicity and the modulation of cell cycle progression with respect to the parent compounds. Thus, despite the in vitro antioxidant activity usually described for catechol derivatives, our results show for the first time the generation of a clastogenic potential, highly indicative of a long-term genetic and cancer risk. The Royal Society of Chemistry 2009.